PE-22-28 (10 mg Vial) Dosage Protocol

Quickstart Highlights

PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels^[4]. Preclinical studies demonstrate rapid antidepressant-like effects, enhanced neurogenesis, and neuroprotection with a favorable safety profile showing no cardiac or metabolic side effects^[2]^[3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.

Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).

Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (µg)	Units (per injection) (mL)
Weeks 1–2	50 µg	1.5 units (0.015 mL)
Weeks 3–4	100 µg	3 units (0.03 mL)
Weeks 5–8	100 µg	3 units (0.03 mL)
Weeks 9–12 (Optional)	150 µg	4.5 units (0.045 mL)
Weeks 13–16 (Optional)	200 µg	6 units (0.06 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency^[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration. Replace vials every 4 weeks to maintain potency.

Peptide Vials (PE-22-28, 10 mg each):

8 weeks ≈ 2 vials
12 weeks ≈ 3 vials
16 weeks ≈ 4 vials

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
16 weeks (4 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100-count boxes
12 weeks: 168 swabs → recommend 2 × 100-count boxes
16 weeks: 224 swabs → recommend 3 × 100-count boxes

View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition^[2]^[4].

Schedule: Daily subcutaneous injections for 12–16 weeks (8 weeks minimum).

Dose Range: 50–200 µg daily with conservative titration; many find 100–150 µg adequate.

Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; replace vials every 4 weeks.

Research Disclaimer